Never directly research monoamine neurotransmitters. By 2021 levels of monoamine neurotransmitters can be regulated every which way and the results in terms of the treatment of mental illnesses are far from spectacular. Dopamine antagonists are neuroleptics. Dopamine antagonists work to the extent that dopamine antagonists work due to dopamine antagonists being neuroleptics.
Serotonin re-uptake inhibitors are in all probability also neuroleptics, but milder neuroleptics than dopamine antagonists with a much better side-effect profile. Serotonin re-uptake inhibitors can inhibit dopaminergic neurotransmission. At the end of the day monoamine neurotransmitters.could once again become important in research but this is early morning..
Drug companies could research dopamine antagonists that target specific brain regions in terms of reducing the side-effect profile of dopamine antagonists. Atypical antipsychotics preferentially enhance dopamine release in the prefrontal cortex as opposed to the limbic system which makes atypical antipsychotics milder neuroleptics than first generation antipsychotics. Risperidone at low dosages has a particularly favorable profile in terms of high serotonin 5-HT2A inverse agonism and low dopamine D2 antagonism.